Table 2.

Neoadjuvant concurrent chemoradiation phase II trials.

Reference	Chemoradiation	N	N2	ORR (% total)	Surgery (% total)	R0 (% surgery)	PCR (% total)	Survival
Taylor et al. (47)	P, 5-FU + 40 Gy	64	50	58	61	NR	14	1 year 61%, median 16 months
Pincus et al. (48)	PE, 5-FU + 40 Gy	31	NR	74	39	100	19	2 years 33%, median 15 months
Faber et al. (49)	P, 5-FU or PE, 5-FU + 40 Gy	85	62	NR	71	NR	20	3 years 40%, median 37 months
Recine et al. (50)	PE, 5-FU + 40 Gy	64	NR	84	36	100	14	3 years 30%, median 13 months; 3 years 69% (resection)
Strauss et al. (51)	VP, 5-FU + 30 Gy	41	33	51	61	96	10	1 year 58% median 16 months
Palazzi et al. (35)	PE + 40 Gy	43	21	70	30	92	7	1 year 58%, 2.5 years 21%
Weiden et al. (52)	P, 5-FU + 30 Gy	85	68	56	52	66	9	Median 13 months
Albain et al. (37)	PE + 45 Gy	126	75	59	71	98	15	2 years 37% (N2); median 13 months (N2)
Favaretto et al. (36)	PE + 51.2 Gy	39	NR	64	51	NR	8	3 years 18%, median 16 months
Choi et al. (53)	VP, 5-FU + 42 Gy	42	42	74	93	87	10	Median 25 months, 5 years 37%
Eberhardt et al. (38)	PE + 45 Gy	94	56	64	66	81	26	Median 20 months (IIIA); 4 years 31% (IIIA) 46% (R0)
Thomas et al. (54)	ICE + 45 Gy	54	25	69	74	85	13	2 years 40%, median 20 months
D’Angelillo et al. (55)	GP + 50.4 Gy	50	29	80	82	88	26	3 years 40%, median 22 months

C, carboplatin; E, etoposide; 5-FU, 5-fluorouracil; G, gemcitabine; I, ifosfamide; NR, not reported; ORR, overall response rate; P, cisplatin; PCR, pathologic complete response; V, vinblastine/vindesine.